Tumor Necrosis Factor-alpha Gene Expression in PBMCs of Iranian Azeri Turkish Patients with Premature Coronary Artery Disease (Age .50 Years)

Overview

Journal Maedica (Bucur)

Specialty General Medicine

Date 2018 Jun 6

PMID 29868134

Citations 4

Authors

Mahssa Hassan-Nejhad

Morteza Bagheri

Kamal Khadem-Vatani

Mir Hossein Seyed Mohammad Zad

Isa Abdi Rad

Behzad Rahimi

Ali Rostamzadeh

Amir Rahimlou

Affiliations

Soon will be listed here.

Abstract

Background: Coronary artery disease is the leading cause of disability and mortality in Iran and worldwide. Tumor necrosis factor-alpha is a pro-inflammatory cytokine that plays a key role in inflammatory cascades and atherosclerosis. It regulates cytokine networks and adhesion molecule expression, and activates several signal transduction pathways, being also known as transducer of cardiovascular diseases, especially premature coronary artery disease.

Objective: The aim of the present study was to investigate tumor necrosis factor-alpha gene expression in Iranian Azeri Turkish patients with premature coronary artery disease (age ≤50 years).

Material And Methods: Eighty four individuals (42 cases and 42 controls) were enrolled in the study. Total RNA was extracted from patients with premature coronary artery disease using RNX-Plus Solution (Cat. No.: RN7713C) and reverse transcribed into cDNA. The tumor necrosis factor-alpha mRNA expression level was evaluated using Real-Time PCR.

Results: The mean ± SE of fold in cases and controls were 1.1±1.08 and 1.6±3.4, respectively. The mean expression of tumor necrosis factor-alpha mRNA (fold) was not statistically different between the tested groups (P value 0.4).

Outcomes: Our outcome failed to find evidence for any association between tumor necrosis factor-alpha mRNA expression and premature coronary artery disease. Large scale, more detailed studies are further needed to prove our results and to propose other mechanisms in the pathophysiology of premature coronary artery disease.

Citing Articles

Transcriptional Activity of Tumor Necrosis Factor Alpha Genes and Their Receptors in Patients with Varying Degrees of Coronary Artery Disease.

Potyka K, Dabek J Int J Mol Sci. 2024; 25(23).

PMID: 39684812 PMC: 11641606. DOI: 10.3390/ijms252313102.

Inflammation Regulation by Bacterial Molecular Patterns.

Guryanova S, Kataeva A Biomedicines. 2023; 11(1).

PMID: 36672691 PMC: 9855958. DOI: 10.3390/biomedicines11010183.

Interleukin-17 is Not Associated with Risk of Premature Coronary Artery Disease in Iranian Turks.

Khadem-Vatani K, Bagheri M, Abdi Rad I, Mahmoudi-Nejad S, Hassan-Nejad M Maedica (Bucur). 2020; 15(2):181-184.

PMID: 32952682 PMC: 7482687. DOI: 10.26574/maedica.2020.15.2.181.

miR-3646 promotes vascular inflammation and augments vascular smooth muscle cell proliferation and migration in progression of coronary artery disease by directly targeting RHOH.

Kang X, Cao S, Ji Z, Zhang Y, Sun S, Shang X Int J Clin Exp Pathol. 2020; 11(12):5830-5839.

PMID: 31949669 PMC: 6963054.

References

Deswal A, Petersen N, Feldman A, Young J, White B, Mann D . Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST). Circulation. 2001; 103(16):2055-9. DOI: 10.1161/01.cir.103.16.2055. View

Rezaee-Zavareh M, Tohidi M, Sabouri A, Ramezani-Binabaj M, Sadeghi-Ghahrodi M, Einollahi B . Infectious and coronary artery disease. ARYA Atheroscler. 2016; 12(1):41-9. PMC: 4834180. View

Cheng Y, An B, Jiang M, Xin Y, Xuan S . Association of Tumor Necrosis Factor-alpha Polymorphisms and Risk of Coronary Artery Disease in Patients With Non-alcoholic Fatty Liver Disease. Hepat Mon. 2015; 15(3):e26818. PMC: 4359363. DOI: 10.5812/hepatmon.26818. View

Zhang C, Xu X, Potter B, Wang W, Kuo L, Michael L . TNF-alpha contributes to endothelial dysfunction in ischemia/reperfusion injury. Arterioscler Thromb Vasc Biol. 2005; 26(3):475-80. DOI: 10.1161/01.ATV.0000201932.32678.7e. View

Bellisarii F, Gallina S, De Caterina R . Tumor necrosis factor-alpha and cardiovascular diseases. Ital Heart J. 2001; 2(6):408-17. View

Pereira T, Rudnicki M, Franco R, Pereira A, Krieger J . Effect of the G-308A polymorphism of the tumor necrosis factor alpha gene on the risk of ischemic heart disease and ischemic stroke: a meta-analysis. Am Heart J. 2007; 153(5):821-30. DOI: 10.1016/j.ahj.2007.02.031. View

Levine B, Kalman J, Mayer L, Fillit H, Packer M . Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med. 1990; 323(4):236-41. DOI: 10.1056/NEJM199007263230405. View

Cassar A, Holmes Jr D, Rihal C, Gersh B . Chronic coronary artery disease: diagnosis and management. Mayo Clin Proc. 2009; 84(12):1130-46. PMC: 2787400. DOI: 10.4065/mcp.2009.0391. View

Livak K, Schmittgen T . Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2002; 25(4):402-8. DOI: 10.1006/meth.2001.1262. View

10.

Zhang H, Xie S, Wang J, Chen Y, Wang Y, Huang T . Tumor necrosis factor-alpha G-308A gene polymorphism and coronary heart disease susceptibility: an updated meta-analysis. Thromb Res. 2011; 127(5):400-5. DOI: 10.1016/j.thromres.2010.12.018. View

11.

Hatmi Z, Tahvildari S, Gafarzadeh Motlag A, Kashani A . Prevalence of coronary artery disease risk factors in Iran: a population based survey. BMC Cardiovasc Disord. 2007; 7:32. PMC: 2200651. DOI: 10.1186/1471-2261-7-32. View

12.

Enayati S, Seifirad S, Amiri P, Abolhalaj M, Mohammad-Amoli M . Interleukin-1 beta, interferon-gamma, and tumor necrosis factor-alpha gene expression in peripheral blood mononuclear cells of patients with coronary artery disease. ARYA Atheroscler. 2015; 11(5):267-74. PMC: 4680074. View

13.

Banerjee A, Newman D, Van den Bruel A, Heneghan C . Diagnostic accuracy of exercise stress testing for coronary artery disease: a systematic review and meta-analysis of prospective studies. Int J Clin Pract. 2012; 66(5):477-92. DOI: 10.1111/j.1742-1241.2012.02900.x. View

14.

McKellar G, McCarey D, Sattar N, McInnes I . Role for TNF in atherosclerosis? Lessons from autoimmune disease. Nat Rev Cardiol. 2009; 6(6):410-7. DOI: 10.1038/nrcardio.2009.57. View

15.

Wilson P, DAgostino R, Levy D, Belanger A, Silbershatz H, Kannel W . Prediction of coronary heart disease using risk factor categories. Circulation. 1998; 97(18):1837-47. DOI: 10.1161/01.cir.97.18.1837. View

16.

Weber C, Noels H . Atherosclerosis: current pathogenesis and therapeutic options. Nat Med. 2011; 17(11):1410-22. DOI: 10.1038/nm.2538. View

17.

Khan D, Ansari W, Khan F . Pro/anti-inflammatory cytokines in the pathogenesis of premature coronary artery disease. J Interferon Cytokine Res. 2011; 31(7):561-7. DOI: 10.1089/jir.2010.0157. View

18.

Feldman A, Combes A, Wagner D, Kadakomi T, Kubota T, Li Y . The role of tumor necrosis factor in the pathophysiology of heart failure. J Am Coll Cardiol. 2000; 35(3):537-44. DOI: 10.1016/s0735-1097(99)00600-2. View

19.

Latini R, Bianchi M, CORREALE E, Dinarello C, Fantuzzi G, Fresco C . Cytokines in acute myocardial infarction: selective increase in circulating tumor necrosis factor, its soluble receptor, and interleukin-1 receptor antagonist. J Cardiovasc Pharmacol. 1994; 23(1):1-6. View

20.

Mohammad A, Jehangeer H, Shaikhow S . Prevalence and risk factors of premature coronary artery disease in patients undergoing coronary angiography in Kurdistan, Iraq. BMC Cardiovasc Disord. 2015; 15:155. PMC: 4650135. DOI: 10.1186/s12872-015-0145-7. View